Literature DB >> 18987784

Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Paul R J Ames1, Annamaria Margarita, Jose Delgado Alves.   

Abstract

The issue of atherosclerosis in the antiphospholipid syndrome (APS) is receiving considerable attention within and without the autoimmune setting. Measurement of arterial intima media thickness (IMT) of is an easy and surrogate means of detecting subclinical atherosclerosis. This technique has been applied to patients with systemic lupus erythematosus (SLE) nand primary APS in the attempt to unravel a possible association between antiphospholipid antibodies and premature atherosclerosis. The available data is reviewed in the light of the most recent atherogenic pathways that may differentially account for premature vascular disease in SLE and primary APS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18987784     DOI: 10.1007/s12016-008-8099-5

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  68 in total

Review 1.  Oxidized low-density lipoprotein biomarkers in atherosclerosis.

Authors:  Sotirios Tsimikas
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

2.  Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome.

Authors:  P R J Ames; C Tommasino; G Fossati; G Scenna; V Brancaccio; F Ferrara
Journal:  Ann Hematol       Date:  2006-11-21       Impact factor: 3.673

3.  Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis, or both?

Authors:  J T Lie
Journal:  J Rheumatol       Date:  1989-06       Impact factor: 4.666

4.  Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity.

Authors:  R C Sorenson; C L Bisgaier; M Aviram; C Hsu; S Billecke; B N La Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-09       Impact factor: 8.311

5.  Carotid intima-media thickness, plaques, and Framingham risk score as independent determinants of stroke risk.

Authors:  Pierre-Jean Touboul; Julien Labreuche; Eric Vicaut; Pierre Amarenco
Journal:  Stroke       Date:  2005-07-14       Impact factor: 7.914

6.  Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease.

Authors:  S Nityanand; C Bergmark; U de Faire; J Swedenborg; G Holm; A K Lefvert
Journal:  J Intern Med       Date:  1995-11       Impact factor: 8.989

7.  Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes.

Authors:  H Esterbauer; G Jürgens; O Quehenberger; E Koller
Journal:  J Lipid Res       Date:  1987-05       Impact factor: 5.922

8.  Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study.

Authors:  L M Taylor; R W Chitwood; R L Dalman; G Sexton; S H Goodnight; J M Porter
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

9.  Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.

Authors:  M Ramos-Casals; M T Campoamor; A Chamorro; G Salvador; S Segura; J C Botero; J Yagüe; R Cervera; M Ingelmo; J Font
Journal:  Lupus       Date:  2004       Impact factor: 2.911

10.  Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus.

Authors:  J R Batuca; P R J Ames; M Amaral; C Favas; D A Isenberg; J Delgado Alves
Journal:  Rheumatology (Oxford)       Date:  2008-11-10       Impact factor: 7.580

View more
  14 in total

1.  New Insights into the Molecular Basis of the Antiphospholipid Syndrome.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  Drug Discov Today Dis Mech       Date:  2011

Review 2.  Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.

Authors:  Roberta Gualtierotti; Martina Biggioggero; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 3.  Atherosclerosis in autoimmune diseases.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Luis R Lopez
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

4.  Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy.

Authors:  Eleftheria Lefkou; Apostolos Mamopoulos; Themistoklis Dagklis; Christos Vosnakis; David Rousso; Guillermina Girardi
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

5.  Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematodes accelerate carotid arteries intima-media thickness changes?

Authors:  Aleksandra Djokovic; Lj Stojanovich; N Stanisavljevic; V Bisenic; S Radovanovic; I Soldatovic; D V Simic
Journal:  Rheumatol Int       Date:  2013-11-15       Impact factor: 2.631

Review 6.  Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases.

Authors:  Anna Broder; Jimmy J Chan; Chaim Putterman
Journal:  Clin Immunol       Date:  2012-12-20       Impact factor: 3.969

Review 7.  Cardiovascular disease in lupus: insights and updates.

Authors:  Jason S Knight; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

8.  Dyslipidaemia in rheumatological autoimmune diseases.

Authors:  Tracey E Toms; Vasileios F Panoulas; George D Kitas
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

9.  Rare Association of Antiphospholipid Antibody Syndrome, Systemic Lupus Erythematosus and Aortic Dissection: A Striking Presentation with Multi-Organ Failure?

Authors:  Firdevs Ulutaş; Veli Çobankara; Aslı Bozdemir; Uğur Karasu
Journal:  Eur J Case Rep Intern Med       Date:  2020-08-27

10.  Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease.

Authors:  A Nandagudi; E C Jury; D Alonzi; T D Butters; S Hughes; D A Isenberg
Journal:  Lupus       Date:  2013-07-17       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.